NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to$4.4M in Q2-2024, an increase of 30% from one quarter ago. Pathology Division revenue in June reached its breakeven point, and the company anticipates continued growth in the next few months. We expect this division’s revenues will reach more than $1.5 million per month by year end, well above its breake ...